Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints - Reuters
- Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Reuters
- Novo Nordisk shares plunge 19% after disappointing trial results; Lilly jumps in premarket CNBC
- Novo Nordisk Falls Most on Record After New Weight Drug Disappoints Bloomberg
- Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump. Investor's Business Daily
- Wall Street eyes inflation data, Novo Nordisk plummets Yahoo Finance